Allink Biotherapeutics secures nearly $50M Series A extension to accelerate global clinical trials for ADC programs and innovative technology platform development

On December 16, 2025, Allink Biotherapeutics, a clinical-stage biotechnology company dedicated to developing next-generation Antibody-Drug Conjugates (ADCs) and multispecific antibody therapeutics for oncology and immune disorders, announced the successful completion of a nearly $50 million Series A extension financing round. This Series A extension was co-led by existing investor Legend Capital and new investor DragonBall Capital, with participation from multiple other prominent new and existing shareholders, including Lanchi Ventures, Yuanbio Venture Capital, 5Y Capital, Long Rock Capital, and Runzhang Venture Capital.

The proceeds from this Series A extension financing will accelerate the global clinical development of Allink Biotherapeutics' two core pipeline assets, which possess significant differentiated advantages. ALK201, a potentially "First-in-Class" and "Best-in-Class" ADC drug targeting FGFR2b, has demonstrated encouraging efficacy signals and a favorable safety profile across multiple tumor types, laying a solid foundation for its potential as a cornerstone therapy for FGFR2b-overexpressing solid tumors. The concurrently advancing ALK202 project, an EGFR/cMET bispecific ADC, has also shown promising early clinical data, indicating its potential to establish a new treatment benchmark in the field of non-small cell lung cancer (NSCLC). Furthermore, the clinical evaluation scope of ALK202 is being expanded to cover additional biomarker-defined tumor types and patient populations.

Based on a biomarker-driven precision development strategy, Allink Biotherapeutics is advancing the clinical development of these two core pipelines at full speed to validate their efficacy across various solid tumors. Allink Biotherapeutics plans to initiate clinical studies on combination therapies involving both projects in the near future, further exploring and expanding their therapeutic potential in first-line patient populations. These strategic initiatives will accelerate the progression of both ALK201 and ALK202 into pivotal registration clinical trials while solidifying their differentiated competitive advantages in their respective target indications.

While continuously advancing its ADC technologies, Allink Biotherapeutics is also actively building a proprietary Masked T-cell Engager (Masked TCE) platform, aiming to drive innovative applications of TCE therapies in the field of solid tumors. In the area of immune and inflammatory diseases, based on a deep understanding of pathogenic mechanisms, Allink Biotherapeutics is progressing several First-in-Class bispecific and multispecific antibody projects, dedicated to providing next-generation therapeutic solutions for patient populations with unmet clinical needs.